Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)
This study has been completed.
Teva Pharmaceutical Industries
Information provided by (Responsible Party):
First received: August 23, 2010
Last updated: October 13, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 2014|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||October 7, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
de Liaño AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.